In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
about
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsCeftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combinationCeftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsImpact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.Pulmonary penetration of piperacillin and tazobactam in critically ill patients.Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection modelIn vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative PathogensPharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of InfectionCombinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.Cephalosporins currently in early clinical trials for the treatment of bacterial infections.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.β-lactam/β-lactamase inhibitor combinations: from then to now.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal DiseaseWhat we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.Pharmacokinetics and Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.In vivo activity of cefquinome against Riemerella anatipestifer using the pericarditis model in the duck.In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa.Oncocin Onc72 is efficacious against antibiotic-susceptible Klebsiella pneumoniae ATCC 43816 in a murine thigh infection model.Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
P2860
Q26747429-C84D8A76-9288-4280-9286-610DA533C6B3Q26998883-94078397-0D9C-4E5C-A8E3-979D8FDCABA2Q28069563-54CB61AD-B7DE-4A38-B8B2-DAB8DEE5229AQ33623078-C65A20A3-794B-4606-A26A-99F32CE0A5F6Q34057425-E08C5812-04C7-4071-9029-1A4392311C19Q34216623-8A7938EE-9E68-495B-A5C4-85B900503AA9Q34298994-6BA22B75-7358-48CF-93F9-74D2B837178BQ34299028-69B3AD8C-6738-49A2-BE71-2275FBE79CC4Q34299064-DC69E1EC-2331-4AB6-9A5C-F0369F703A25Q34393008-7AAF5F80-3296-431A-9028-718FA059B2D1Q35004269-A29FF690-DF85-45B8-8996-3DFE534ADAE9Q35607735-E1C653BB-CB15-42FF-B591-EF2883AC7BF9Q35960643-9450E179-761A-4414-B970-A2072027003DQ36438924-2E520991-D8A1-4DD6-B7C0-0D5543D7DE25Q36730017-D9C6A60D-0C3D-424C-9590-A71AFB5F8355Q37308807-19869C6E-BB5E-4A39-BFBD-471B03621257Q37335781-1EB04166-A95B-4B79-A46F-0C489A311453Q37428654-8F00774E-4E8A-4D49-9DD6-76976206279DQ38222497-44FE9B40-FCC7-485A-94B0-C52115C86B74Q38241417-AF05955D-C85C-4461-99AF-C5827A8ACDAAQ38262205-199B2C10-98EA-4E2B-BE89-6FB88FEEE233Q38264182-0603D9C4-919E-40A1-8D9D-1499F594FB4EQ38296151-A55AFC06-3105-4BEE-9FAB-94D2B27AFBC8Q38541624-7ADBA988-6F93-4DD0-AC1D-6366B01BC186Q38544744-B9A45DBB-E6F2-4D9B-864A-C7C7C55215C3Q38672016-3CB97096-2263-492D-A845-FF02CC65A9DEQ38690748-F0084566-CDFE-4C95-9DCA-F983F7BACF72Q38718394-50A18798-3ABE-46D7-91CC-3FEC712ADDFCQ38872130-33889616-55D4-45E0-B12E-1CC5F43A1979Q38934400-0F30EE7B-CE29-4D28-B41C-4DFA330D551BQ39001350-464E3D67-AB86-4C05-8FAB-C10AF6490A0DQ39066154-4BD766AC-B7DB-4E8B-BF69-FCF5137416F6Q39120027-E84EC711-3C65-487C-AE92-94346ED26B3AQ39683724-84F14242-B9BD-4B06-8F58-98388C3EA723Q39940279-020ADD82-98CA-4E84-A0CB-CF0ADD38AAA9Q40052714-E4EFCAE1-F381-4079-BF58-77B6B930B844Q40330083-0AF739BB-4904-4EE5-9D77-DB010257410FQ40401367-6EF08744-085E-437F-9880-0D97A001F0ABQ41236257-ED90BEDE-62F7-420D-9116-23609B853182Q42109987-33FCA728-EA8A-47E5-9278-077E7554ABA7
P2860
In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@ast
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@en
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@nl
type
label
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@ast
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@en
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@nl
prefLabel
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@ast
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@en
In vivo activities of ceftoloz ...... he thighs of neutropenic mice.
@nl
P2860
P356
P1476
In vivo activities of ceftoloz ...... the thighs of neutropenic mice
@en
P2093
P2860
P304
P356
10.1128/AAC.01590-12
P407
P50
P577
2012-12-28T00:00:00Z